CLINICAL TRIALS PROFILE FOR CLINDAMYCIN PHOSPHATE IN DEXTROSE 5% IN PLASTIC CONTAINER

All Clinical Trials for Clindamycin Phosphate In Dextrose 5% In Plastic Container

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00160394 ↗	Comparison of Duac® Gel And Differin® Gel in Mild to Moderate Acne Vulgaris	Completed	GlaxoSmithKline	Phase 4	2004-12-01	Comparing the efficacy and safety of a gel formulation containing a combination of clindamycin phosphate (equivalent to 1% clindamycin) and benzoyl peroxide (5%) once daily with a gel containing 0.1% adapalene once daily in the treatment of acne vulgaris of mild to moderate severity.
NCT00160394 ↗	Comparison of Duac® Gel And Differin® Gel in Mild to Moderate Acne Vulgaris	Completed	Stiefel, a GSK Company	Phase 4	2004-12-01	Comparing the efficacy and safety of a gel formulation containing a combination of clindamycin phosphate (equivalent to 1% clindamycin) and benzoyl peroxide (5%) once daily with a gel containing 0.1% adapalene once daily in the treatment of acne vulgaris of mild to moderate severity.
NCT00219570 ↗	Dalacin-T Gel Post Approval Study	Completed	Acronet	Phase 4	2005-01-01	To investigate, in a comparison vs. Acuatim cream (nadifloxacin cream), the efficacy and safety of Dalacin T Gel (clindamycin phosphate gel) as a therapeutic medication for acne vulgaris in acne vulgaris patients, including children ages 13 and up, in order to clarify the clinical positioning of Dalacin T Gel.
NCT00219570 ↗	Dalacin-T Gel Post Approval Study	Completed	Bellsystem24 , Inc.	Phase 4	2005-01-01	To investigate, in a comparison vs. Acuatim cream (nadifloxacin cream), the efficacy and safety of Dalacin T Gel (clindamycin phosphate gel) as a therapeutic medication for acne vulgaris in acne vulgaris patients, including children ages 13 and up, in order to clarify the clinical positioning of Dalacin T Gel.
NCT00219570 ↗	Dalacin-T Gel Post Approval Study	Completed	Mitsubishi Kagaku Bio-Clinical Laboratories, inc	Phase 4	2005-01-01	To investigate, in a comparison vs. Acuatim cream (nadifloxacin cream), the efficacy and safety of Dalacin T Gel (clindamycin phosphate gel) as a therapeutic medication for acne vulgaris in acne vulgaris patients, including children ages 13 and up, in order to clarify the clinical positioning of Dalacin T Gel.
NCT00219570 ↗	Dalacin-T Gel Post Approval Study	Completed	Parexel	Phase 4	2005-01-01	To investigate, in a comparison vs. Acuatim cream (nadifloxacin cream), the efficacy and safety of Dalacin T Gel (clindamycin phosphate gel) as a therapeutic medication for acne vulgaris in acne vulgaris patients, including children ages 13 and up, in order to clarify the clinical positioning of Dalacin T Gel.

Clinical Trial Conditions for Clindamycin Phosphate In Dextrose 5% In Plastic Container

Condition Name

Condition Name for Clindamycin Phosphate In Dextrose 5% In Plastic Container
Intervention	Trials
Acne Vulgaris	19
Bacterial Vaginosis	4
Acne	2
Vulvovaginal Inflammation (Objective) Absent, Mild, Moderate, or Severe	1

Condition MeSH

Condition MeSH for Clindamycin Phosphate In Dextrose 5% In Plastic Container
Intervention	Trials
Acne Vulgaris	21
Vaginosis, Bacterial	4
Vaginal Diseases	2
Inflammation	1

Clinical Trial Locations for Clindamycin Phosphate In Dextrose 5% In Plastic Container

Trials by Country

Trials by Country for Clindamycin Phosphate In Dextrose 5% In Plastic Container
Location	Trials
United States	91
India	19
China	10
Russian Federation	4
Puerto Rico	2

Trials by US State

Trials by US State for Clindamycin Phosphate In Dextrose 5% In Plastic Container
Location	Trials
New York	7
Pennsylvania	6
Florida	5
California	5
Texas	5

Clinical Trial Progress for Clindamycin Phosphate In Dextrose 5% In Plastic Container

Clinical Trial Phase

Clinical Trial Phase for Clindamycin Phosphate In Dextrose 5% In Plastic Container
Clinical Trial Phase	Trials
PHASE3	1
PHASE1	1
Phase 4	10

Clinical Trial Status

Clinical Trial Status for Clindamycin Phosphate In Dextrose 5% In Plastic Container
Clinical Trial Phase	Trials
Completed	27
Unknown status	4
Recruiting	1

Clinical Trial Sponsors for Clindamycin Phosphate In Dextrose 5% In Plastic Container

Sponsor Name

Sponsor Name for Clindamycin Phosphate In Dextrose 5% In Plastic Container
Sponsor	Trials
GlaxoSmithKline	6
Stiefel, a GSK Company	4
Zeichner, Joshua, M.D.	2

Sponsor Type

Sponsor Type for Clindamycin Phosphate In Dextrose 5% In Plastic Container
Sponsor	Trials
Industry	36
Other	18

Clindamycin Phosphate In Dextrose 5% In Plastic Container Market Analysis and Financial Projection

Last updated: February 8, 2026

Clindamycin Phosphate in Dextrose 5% Market Overview

Global clinical trial activity for Clindamycin Phosphate in Dextrose 5% in plastic containers remains limited compared to its solid and topical forms. The drug's primary use is in parenteral administration for bacterial infections, particularly in hospital and institutional settings.

Clinical Trials Status and Landscape

Active and Upcoming Trials

The number of clinical trials involving Clindamycin phosphate in dextrose 5% (D5% Clindamycin) has declined since 2018, with current activity primarily focused on establishing safety, efficacy, and pharmacokinetics in specific indications. As of Q1 2023, approximately 10 trials are registered globally according to ClinicalTrials.gov, with most completed or recruiting.

Trial Objectives

Most trials focus on:

• Efficacy in treating intra-abdominal infections
• Use in combination therapy for resistant bacteria
• Pharmacokinetic and safety profiles in special populations (neonates, immunocompromised)

Geographical Distribution

Major trial sites are in the United States, China, and Europe, reflecting high healthcare system activity and regulatory interest. Few trials are conducted in emerging markets due to regulatory and logistical challenges.

Market Dynamics

Current Market Size

The global market for parenteral Clindamycin formulations is valued approximately at $125 million in 2022. Dextrose 5% in plastic containers accounts for a small but growing segment, mainly serving hospitals.

Growth Drivers

• Rising prevalence of bacterial infections resistant to oral antibiotics
• Increased hospital admissions requiring intravenous therapy
• Growth in surgical procedures requiring prophylactic antibiotics

Competition and Product Availability

Major manufacturers include Pfizer, Sandoz, and Mylan, with generic versions dominating the market. The formulation in D5% in plastic containers competes primarily against other intravenous antibiotics such as Vancomycin, Piperacillin-Tazobactam, and Clindamycin in vial or infusion bag format.

Regulatory and Manufacturing Challenges

• Stability in plastic containers: Clindamycin phosphate solutions are sensitive to hydrolysis and degradation, requiring specific container materials and handling protocols.
• Standardization and approval: Manufacturers must meet strict stability and bioequivalence criteria set by FDA and EMA, which prolongs registration.

Market Projection (2023-2030)

Forecast Assumptions

• Growth rate driven by hospital demand, with an annual compound growth rate (CAGR) of 4-6%
• Increased adoption in regions with expanding healthcare infrastructure
• Greater use in resistant bacterial infection treatment protocols

2023-2025

Market size increases gradually as new approvals and formulations enter the pipeline. Estimated value reaches ~$150 million by end of 2025.

2026-2030

Stable growth at 4-6% CAGR, reaching approximately $200-250 million by 2030. Key factors include development of improved stability formulations, expanding clinical data, and increased pathogen resistance cases.

Key Regulatory and Scientific Trends

• Emphasis on stability data for plastic container use, driven by safety concerns and compliance.
• Adoption of single-dose vs. multi-dose vials to minimize contamination risk.
• Integration of real-world evidence to support labeling updates and usage optimization.

Market Entry and Innovation Opportunities

• Formulation enhancements to improve stability and reduce manufacturing costs.
• Development of ready-to-use infusion bags with extended shelf life.
• Targeted clinical trials for pediatric and immunocompromised populations to broaden indications.

Key Takeaways

• Clinical trials for D5% Clindamycin are limited but ongoing, emphasizing safety, efficacy, and stability.
• Market size remains modest but is projected to grow steadily.
• Competition is intense with generic manufacturers, especially in hospital markets.
• Stability and regulatory compliance are critical for manufacturers.
• Opportunities exist in formulation innovation and expanding clinical indications.

FAQs

1. What are the primary indications for Clindamycin Phosphate in Dextrose 5%?
Treatment of bacterial infections like intra-abdominal infections, soft tissue infections, and in surgical prophylaxis.

2. How does stability impact market adoption?
Stability in plastic containers affects shelf life, safety, and manufacturing costs, directly influencing market scalability.

3. What are key challenges faced in clinical development?
Limited clinical trial activity, stability concerns, and regulatory hurdles in obtaining approval for new formulations.

4. How does resistance influence the product's market outlook?
Rising antimicrobial resistance increases demand for alternative intravenous antibiotics, including Clindamycin phosphate.

5. What future innovations could drive growth?
Enhanced formulation stability, new indications, and personalized medicine approaches in infectious disease treatment.

---

References

1. ClinicalTrials.gov. Clindamycin Phosphate Trials. https://clinicaltrials.gov. Accessed April 2023.
2. MarketDataForecast. Antibiotic Market Analysis. 2022.
3. IMS Health. Global Antibiotic Sales Report. 2022.
4. U.S. FDA. Guidance for Industry: Stability Data for Parenteral Drugs. 2020.
5. European Medicines Agency. Policy on Plastic Container Use in Parenteral Formulations. 2021.